Tricento transcatheter heart valve implantation in a redo setting for the treatment of torrential tricuspid valve regurgitation

2021 ◽  
Keyword(s):  
Medical Treatment ◽  
Heart Valve ◽  
Tricuspid Valve ◽  
Treatment Option ◽  
Valve Regurgitation ◽  
Tricuspid Valve Regurgitation ◽  
Transcatheter Heart Valve ◽  
Tricuspid Valve Insufficiency ◽  
Valve Insufficiency ◽  
Valve Implantation

Surgery on the tricuspid valve is well established in specialized centers because tricuspid valve insufficiency is frequently encountered and is often functional in nature. With the increasing adoption of catheter-based treatments, there is a growing interest in and need for interventional treatments for tricuspid valve insufficiency. The Tricento heart valve is a gentle, less invasive, catheter-based treatment option for patients not suited for surgery who are receiving optimized medical treatment.

Pulsatile Varicose Veins Caused by Tricuspid Valve Regurgitation

1990 ◽  
Vol 5 (3) ◽  
pp. 189-191 ◽  
Author(s):  
J. Dayantas ◽  
A.C. Liatas ◽  
M. Lazarides
Keyword(s):  
Tricuspid Valve ◽  
Varicose Veins ◽  
Venous Pressure ◽  
Postoperative Recovery ◽  
Recent Experience ◽  
Tricuspid Valve Regurgitation ◽  
Prosthetic Valves ◽  
Tricuspid Valve Insufficiency ◽  
Valve Insufficiency ◽  
Uncommon Case

We report an uncommon case of pulsatile varicose veins in a young woman caused by tricuspid valve insufficiency of rheumatic origin combined with an incompetent valve at the sapheno–femoral junction. She was treated with limited stripping of the great saphenous vein and local varicosities were excised. Postoperative recovery was complicated by a large haematoma in the thigh. Following our recent experience we believe that patients like this, with elevated venous pressure and requiring anticoagulant therapy for prosthetic valves, should be treated with sapheno–femoral dissociation alone.

Jailing of a Pacemaker Lead During Tricuspid Valve-in-Valve Implantation With an Edwards SAPIEN XT Transcatheter Heart Valve

2015 ◽  
Vol 31 (6) ◽  
pp. 819.e9-819.e11 ◽  
Author(s):  
Jean-Michel Paradis ◽  
Mathieu Bernier ◽  
Christine Houde ◽  
Éric Dumont ◽  
Daniel Doyle ◽  
...  
Keyword(s):  
Heart Valve ◽  
Tricuspid Valve ◽  
Pacemaker Lead ◽  
Transcatheter Heart Valve ◽  
Edwards Sapien ◽  
Valve In Valve ◽  
Valve Implantation

Percutaneous Inferior Vena Cava Valve Implantation May Improve Tricuspid Valve Regurgitation and Cardiac Output: Lessons Learned

2020 ◽  
Vol 15 (6) ◽  
pp. 577-580
Author(s):  
Seyed Hossein Aalaei-Andabili ◽  
Anthony A. Bavry ◽  
Calvin Choi ◽  
George Arnaoutakis ◽  
R. David Anderson ◽  
...  
Keyword(s):  
Cardiac Output ◽  
Inferior Vena Cava ◽  
Tricuspid Valve ◽  
Inferior Vena ◽  
Vena Cava ◽  
Left Ventricular Ejection ◽  
Valve Regurgitation ◽  
Tricuspid Valve Regurgitation ◽  
Transcatheter Valve ◽  
Valve Implantation

Tricuspid valve regurgitation (TR) can be associated with poor prognosis. Transcatheter valve technology was adopted to treat the upstream effects of severe TR by placing a transcatheter valve in the inferior vena cava (IVC). In this study, we report off-label transcatheter valve implantation into the stented IVC in patients with severe TR for compassionate use. From September 2018 to February 2020, 6 inoperable patients with severe TR who failed medical treatment underwent percutaneous caval valve implantation (CAVI). Severity of TR was confirmed by intraoperative transesophageal echocardiography. Z-stents (Cook, Inc., Bloomington, IN, USA) were placed in the proximal IVC, and then a transcatheter valve was deployed in the suprahepatic cava without rapid pacing. Six patients, 2 females and 4 males, with a mean ± SD age of 74.7 ± 8.0 years were included. The procedure was successfully performed in all 6 patients (100%) employing a 29-mm SAPIEN 3 valve (Edwards Lifesciences, Irvine, CA, USA) with supranominal volume. No procedural complication was detected. At 30 days, TR improved from severe to trace in 1 patient, to mild-moderate in 3 patients, and 2 patients remained with severe TR. Among patients with improved TR, left ventricular ejection fraction increased from 47.5% ± 18.5% to 55% ± 20.4% ( P = 0.014). No patient had readmission at 30 days. Four patients needed rehospitalization within 6 months. Percutaneous CAVI is feasible and can be considered as a short-term palliative measure in patients with severe TR. CAVI can improve TR and potentially improve cardiac output in selected patients.

scholarly journals Effect of concomitant atrioventricular valve regurgitation on the outcome after transcatheter aortic-valve implantation

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
M Drakopoulou ◽  
M Karmpalioti ◽  
C Simopoulou ◽  
G Oikonomou ◽  
A Apostolos ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Tricuspid Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Valve Regurgitation ◽  
Tricuspid Valve Regurgitation ◽  
Transcatheter Aortic Valve ◽  
Significant Difference ◽  
Aortic Valve Implantation ◽  
Valve Implantation ◽  
The Impact

Abstract Background Many patients undergoing transcatheter aortic valve implantation (TAVI) have concomitant mitral regurgitation (MR) of moderate grade or more. The impact of coexistent tricuspid regurgitation (TR) remains to be determined. Methods Patients with severe and symptomatic aortic stenosis [effective orifice area (EOA)≤1cm2] referred for TAVI at our institution were consecutively enrolled. Prospectively collected demographic, laboratory and echocardiographic data were retrospectively analysed. Patients were divided into 4 groups according to MR and TR severity pre-procedurally: no/mild MR and TR, moderate/severe MR, moderate/severe TR, moderate/severe MR and TR. Primary clinical endpoint was all-cause mortality, as defined by the criteria proposed by the Valve Academic Research Consortium2. Results A total of 244 consecutive patients were enrolled in the study: 148 (60.7%) patients no/mild MR and TR, 32 (13.1%) moderate/severe MR, 35 (14.3%) moderate/severe TR, 29 (11.9%) moderate/severe MR and TR pre-procedurally. There was significant difference in pre-procedural pulmonary artery systolic pressure (PASP) among groups (no/mild MR and TR: 40.8±10 mmHg, moderate/severe MR: 46.6±11.2 mmHg, moderate/severe TR: 49.9±13mmHg, moderate/severe MR and TR: 59.8±15.2mmHg, p<0.0001). The Kaplan–Meier curves for 2 year mortality showed that the severity of TR was associated with poor survival. Interestingly, patients with moderate/severe MR and TR had the worse survival (no/mild MR and TR (91.2%), moderate/severe MR (78.1%), moderate/severe TR (62.9%), moderate/severe MR and TR (62.1%), p<0.0001). Conclusion The presence of concomitant moderate or severe mitral and tricuspid valve regurgitation was associated with the higher mortality. This suggests that a thorough evaluation of the mechanisms underlying concomitant mitral and tricuspid valve regurgitation should be performed to determine the best strategy for avoiding TAVI-related futility. FUNDunding Acknowledgement Type of funding sources: None.

Sign in / Sign up

Export Citation Format

Share Document